Abbott Laboratories (Pakistan) Limited reported a strong financial performance for the year ended December 31st, 2025
Filed as: Financial Results for the Year Ended December 31, 2025
Summary
Abbott Laboratories (Pakistan) Limited reported a strong financial performance for the year ended December 31st, 2025, with net profit reaching Rs 7.97 billion and sales net of Rs 75.40 billion, indicating robust growth.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Net Profit | PKR 7.97 billion | PKR 5.23 billion | +52.2% |
| Sales Net | PKR 75.40 billion | PKR 68.18 billion | +10.6% |
| Gross Profit | PKR 26.45 billion | PKR 19.74 billion | +34.0% |
| Earnings Per Share | PKR 81.37 | PKR 53.46 | +52.2% |
| Cash and Cash Equivalents | PKR 13.34 billion | PKR 6.18 billion | +115.8% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Net profit increased to Rs 7.97 billion, a significant rise from Rs 5.23 billion in 2024, reflecting strong profitability.
- Sales net grew to Rs 75.40 billion from Rs 68.18 billion in 2024, showcasing a healthy revenue growth.
- Earnings per share rose to Rs 81.37 from Rs 53.46, indicating improved shareholder value.
Abbott Laboratories (Pakistan) Limited (ABOT) on Nafa
Last price Rs 1,000.00 · Pharmaceuticals · You can own ABOT shares from your phone.
More ABOT announcements
- NoticeTransmission of Quarterly Reports for the Period Ended September 30, 2026
- Financial resultAbbott Laboratories (Pakistan) Limited reported a strong financial performance for the nine months ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30, 2026
- NoticeBoard Meeting
- NoticeTransmission of Quarterly Financial Statements for the Period Ended June 30, 2026
- NoticeBoard Meeting
- NoticeRe-Appointment of Chairman
Source: Abbott Laboratories (Pakistan) Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.